Skip to main content

    Tenax Therapeutics (TENX) receives Neutral downgrade from Guggenheim

    GNG Research Market News

    By GNG Research

    Guggenheim downgraded Tenax Therapeutics Inc (TENX) to Neutral from Buy on August 31, 2026.

    The past 90 days include five active firms, with one rating the stock bullish. 10 analysts set consensus price targets as of October 30, 2026, with a mean of $9.82, a median of $5.10 and a range of $4.04 to $36.75.

    The Q4 FY2026 consensus calls for -$0.36 in EPS on $0 in revenue. The next earnings date is March 8, 2027.